Background Plasma gelsolin (pGSN) is an important part of the blood actin buffer that
prevents negative consequences of possible F-actin deposition in the microcirculation and …

The SARS-CoV-2 spike protein has been shown to disrupt blood–brain barrier (BBB)
function, but its pathogenic mechanism of action is unknown. Whether angiotensin …

Background To date, recombinant tissue plasminogen activator (rtPA) is the only approved
drug for ischemic stroke. It is intravenously administered functioning as a thrombolytic agent …

As researchers across the globe have focused their attention on understanding SARS-CoV-
2, the picture that is emerging is that of a virus that has serious effects on the vasculature in …

Background Microglia is the major contributor of post-stroke neuroinflammation cascade and
the crucial cellular target for the treatment of ischemic stroke. Currently, the endogenous …

Background and Purpose—Subarachnoid hemorrhage (SAH) pathophysiology involves
neurovascular proteolysis and inflammation. How these 2 phenomena are related remains …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uses the Angiotensin
converting enzyme 2 (ACE2) receptor present on the cell surface to enter cells. Angiotensin …

SARS-CoV-2 has been reported to show a capacity for invading the brains of humans and
model animals. However, it remains unclear whether and how SARS-CoV-2 crosses the …

Patients with coronavirus disease 2019 (COVID-19) have been frequently reported to exhibit
neurological manifestations and disruption of the blood-brain barrier (BBB). Among the risk …

Abstract Coronavirus disease 19 (COVID-19) is a respiratory illness caused by severe acute
respiratory syndrome coronavirus-2 (SARS-CoV-2). COVID-19 pathogenesis causes …